A unique collaboration of multidisciplinary experts from the European Dermatology Forum
(EDF), the European Association of Dermato-Oncology (EADO), and the European …

The development of brain metastases occurs in 10–20% of all patients with cancer. Brain
metastases portend poor survival and contribute to increased cancer mortality and morbidity …

Background Nivolumab combined with ipilimumab have shown activity in melanoma brain
metastasis (MBM). However, in most of the clinical trials investigating immunotherapy in this …

Significant advancements have been made in the treatment of advanced melanoma with the
use of immune checkpoint inhibitors, novel immunotherapies, and BRAF/MEK-targeted …

Immunotherapy combinations are being investigated to expand the benefit of immune
checkpoint blockade across many cancer types. Radiation combinations, in particular using …

Purpose: Preclinical data suggest that radiotherapy (RT) is beneficial in combination with
immune checkpoint blockade. Clinical trials have explored RT with single-agent immune …

Introduction The brain is a common site of metastatic disease for patients with advanced
melanoma. Brain metastasis portends a poor prognosis, often causing deterioration in …

Introduction/purpose This study assessed long‐term clinical and radiological outcomes
following treatment with combination stereotactic radiosurgery (SRS) and immunotherapy …

Introduction: Brain metastases (BM) are a frequent complication of metastatic cancer. Due to
the wider availability and application of screening procedures, an increasing fraction of …

Background Patients with melanoma brain metastasis (MBM) still carry a dismal prognosis.
Preclinical data originated in xenograft models showed that buparlisib therapy was highly …